CAIRO – 11 February 2018: "Zepatier was introduced in the Egyptian market to treat virus C, after being approved by the Ministry of Health,” professor of liver and gastrointestinal tract Ali al-Qadi said in a statement to Egypt Today.
The medicine is not included in the system of treatment at the expense of the state and health insurance due to its high price, as the value of the treatment course costs up to 50 thousand pounds.
Qadi added that this medicine is totally different from others in the market as it cures early cases without severe liver fibrosis and no other diseases associated with virus C, and patients who did not respond to previous treatments and suffer from other diseases such as diabetes, high / low blood pressure, and heart diseases, as well as patients with renal diseases and renal failure.
Qadi explained that it is given alone, without the addition of any other drugs and that the duration of treatment is only three months, therefore considered the most appropriate drug for virus C patients with kidney failure as it is completely safe for kidneys, adding that there is no Egyptian alternative to it so far.
Qadi further stressed that the medicine achieved results up to 100 percent in many cases.
ZEPATIER is a breakthrough treatment for hepatitis C; it is a combination of two different medicines—Elbasvir and Grazoprevir—in a single pill. ZEPATIER works by blocking proteins the virus needs to replicate.